Hyperfine, Inc. (HYPR) Q2 2025 Earnings Call Transcript

Hyperfine, Inc. (HYPR) reported Q2 2025 revenue of $2.7 million, a 26% sequential increase, driven by the sale of 8 systems, including the first next-generation Swoop system following its FDA clearance. The company achieved an 800 basis point sequential gross margin expansion to 49% and reduced cash burn by 19% to $8.1 million. Management emphasized the successful launch of its next-generation AI-powered Swoop system and Optive AI software, which has garnered positive market reception and is poised to drive significant growth across hospital, new office, and international channels. Hyperfine reiterated its full-year 2025 revenue growth guidance of 10-20% over 2024, anticipating a substantial ramp-up in the second half, and expects its cash runway to extend through the end of 2026, signaling a critical inflection point for the business.

Analysis

Hyperfine, Inc. reported a significant operational and strategic inflection point in its Q2 2025 results, demonstrating strong sequential progress despite a flat net loss per share. The company generated $2.7 million in revenue, a 26% sequential increase, driven by the sale of eight systems. Critically, this included the first commercial sale of its next-generation Swoop system just 30 days after receiving FDA clearance, signaling rapid execution. Financial discipline was evident, with gross margins expanding 800 basis points sequentially to 49.3% and cash burn, excluding financing, declining 19% to $8.1 million. Management has lowered its full-year cash burn guidance to a range of $27-29 million and projects a cash runway through the end of 2026.

The core of the investment thesis now rests on the commercial ramp-up of the new Swoop system and its accompanying Optive AI software. Management reports an overwhelmingly positive market response, with the new system's image quality noted as approaching that of conventional 1.5T MRI scanners, unlocking a total addressable market estimated at over $6 billion. This technological leap supports a 15% MSRP premium on the new system, which should bolster future revenue and margins. The company is executing a multi-channel growth strategy, transitioning its new neurology office initiative from a pilot to a full commercial launch, expanding use cases in hospitals, and progressing with international approvals. The company reaffirmed its full-year revenue growth guidance of 10-20% over 2024, which explicitly requires a substantial acceleration in the second half, with Q3's sequential revenue increase guided to be 50% larger than the Q1-to-Q2 improvement, followed by a more significant step-up in Q4.

Key Decisions for Investors

• Investors should closely monitor the company's execution on its guided second-half revenue acceleration, as the reaffirmed 10-20% full-year growth target is heavily dependent on a significant increase in system placements compared to the first half.
• The successful launch and market adoption of the higher-priced next-generation Swoop system should be watched as a primary driver for both top-line growth and gross margin expansion toward and beyond the 50% level.
• Pay close attention to commercial traction in the newly launched neurology office channel and progress of the Neuro PMR and PRIME clinical studies, as positive adoption rates are critical for validating the expanded market opportunity.
• While management has improved its cash burn forecast and projects a runway through 2026, the rate of revenue growth relative to operating expenses remains a crucial metric for assessing the company's path to long-term profitability.